

anti-CD56
anti-CD56-CpG
p425
CD69 MFI
2000
1500
1000
500
0
0.0001
0.01
1
100
10000
nM

FIG. 1



anti-CD56
anti-CD56-CpG
p425
CD69 MFI
2000
1500
1000
500
0
0.0001
0.01
1
100
10000
nM

FIG. 2



anti-Sirpα 1
anti-Sirpα 1-CpG
anti-Sirpα 2
anti-Sirpα 2-CpG
p425
CD14+ count
80000
60000
40000
20000
0
0.001
0.01
0.1
1
10
100
1000
nM

FIG. 3



anti-Sirpα 1
anti-Sirpα 1-CpG
anti-Sirpα 2
anti-Sirpα 2-CpG
p425
CD14+ count
150000
100000
50000
0
0.001
0.01
0.1
1
10
100
1000
nM

FIG. 4



tBuDS-Ph (ortho)
Z = O (PO) or S (PS)
dT(DBCO)
Butyl triester (R = n-butyl)
Ethyl triester (R = ethyl)
Homopropargyl triester (R = homopropargyl)
PEG3-NH2 triester (n = 1)
Z = O (PO) or S (PS)
PEG2-NH2 triester (n = 0)
Z = O (PO) or S (PS)
DBCO-TEG
DBCO-T (X=O, R'=H)
DBCO-t (X=S, R'=H)
DBCO-T (X=O, R'=n-butyl)
DBCO-t (X=S, R'=n-butyl)
DBCO-NH-PEG3 triester (n =1)
Z = O (PO)
Z = S (PS)
DBCO-NH-PEG2 triester (n = 0)
Z = O (PO)
Z = S (PS)
X3 abasic spacer
X5-DBCO (PO) (Z = O)
x5-DBCO (PS) (Z = S)

FIG. 5



DBCO-C6-dT
PEG4 dT triester (PS) (Z = S)
PEG4 dT triester (PO) (Z = O)
dT PEG2-NH2 triester (PS) (Z = S; n = 0)
dT PEG2-NH2 triester (PO) (Z = O; n = 0)
dT PEG3-NH2 triester (PS) (Z = S; n = 1)
dT PEG3-NH2 triester (PO) (Z = O; n = 1)
DBCO-TEG-C6-SS-C6-
Z = O or S
RT = bond to a targeting moiety
TCO

FIG. 6



CT26
PBS
10 mpk Anti- Sirpα 1 conjugate (2q3)
10 mpk unconjugated Anti- Sirpα (2q3)
Tumor volume
(mm³ ± SEM)
2000
1500
1000
500
0
5
10
15
20
25
Day Post Tumor Implantation

FIG. 7A



CT26
3 mpk Anti- Sirpα 1 conjugate (2q3)
3 mpk Anti- Sirpα 2 conjugate (2q3)
PBS
Tumor volume
(mm³ ± SEM)
2000
1500
1000
500
0
5
10
15
20
25
Day Post Tumor Implantation

FIG. 7B



CT26
PBS
1 mpk Anti- Sirpα 1 conjugate (2q3)
0.3 mpk Anti- Sirpα 1 conjugate (2q3)
0.1 mpk Anti- Sirpα 1 conjugate (2q3)
Tumor volume (mm3), mean ± SEM
2500
2000
1500
1000
500
0
9
12
15
18
21
24
27
Days Post Tumor Implantation

FIG. 7C



MC38
PBS
10 mpk Anti- Sirpα 1 conjugate (2q3)
Mean Tumor Size (mm3)
2000
1500
1000
500
0
0
4
8
12
16
20
24
Tumor post-implantation

FIG. 7D



CT26
PBS
1 mpk Anti- Sirpα 1 conjugate (2q3)
1 mpk Anti- Sirpα 1 conjugate (2q7)
Tumor volume (mm³), mean ± SEM
2500
2000
1500
1000
500
0
10
15
20
25
30
Days Post Tumor Implantation

FIG. 8A



CT26
PBS
1 mpk Anti- Sirpα 1 conjugate (2q3)
1 mpk Anti- Sirpα 1 conjugate (2q7)
Percent survival
100
50
0
0
10
20
30
40
50
60
70
Time

FIG. 8B